Literature DB >> 24809673

In breast cancer patients sentinel lymph node metastasis characteristics predict further axillary involvement.

Ildiko Illyes1, Anna-Maria Tokes, Attila Kovacs, A Marcell Szasz, Bela A Molnar, Istvan A Molnar, Ilona Kaszas, Zsuzsanna Baranyak, Zsolt Laszlo, Istvan Kenessey, Janina Kulka.   

Abstract

The aim of the study was to correlate various primary tumor characteristics with lymph node status, to examine sentinel lymph node (SLN) metastasis size and non-SLN axillary involvement, to look for a cut-off size/number value possibly predicting additional axillary involvement with more accuracy and to examine the relationship of SLN metastasis size to overall survival. Of 301 patients who underwent SLN biopsy, 75 had positive SLNs. The size of the metastases was measured. For different size categories, association with the prevalence of non-SLN metastases was assessed. Associations between metastasis size and tumor characteristics and overall survival (OS) were studied. The prevalence of axillary lymph node (ALN) involvement was not significantly different between cases with micrometastasis or macrometastasis in SLNs (p = 0.124). However, for metastases larger than 6, 7, and 8 mm, the prevalence of ALN involvement was significantly higher (p = 0.046, 0.022, and 0.025). OS was significantly lower in SLN-positive than in SLN-negative cases (p = 0.0375). Primary tumor size larger than 20 mm was associated with a significantly higher incidence of SLN metastasis (p < 0.001), and primary tumor size over 26 mm was associated with additional positive non-SLN (p < 0.001). Higher mitotic index (≥ 7) in primary tumors was significantly (p < 0.001) associated with ALN involvement in SLN-positive cases, whereas higher Ki67 labeling index was not significantly correlated with SLN or ALN involvement. Lymphovascular invasion (LVI) in primary tumors was significantly correlated with SLN positivity (p < 0.001) but not with further ALN involvement or OS. Tumor size and LVI are predictive for SLN metastasis. Mitotic index, primary tumor size, and larger volume SLN involvement are determinants of further ALN involvement. SLN metastasis size over 6 mm is a strong predictor of further axillary involvement. OS is shorter in the presence of positive SLN.

Entities:  

Mesh:

Year:  2014        PMID: 24809673     DOI: 10.1007/s00428-014-1579-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  57 in total

1.  Prediction of non-sentinel lymph node status in breast cancer with a micrometastatic sentinel node.

Authors:  P Schrenk; P Konstantiniuk; S Wölfl; S Bogner; A Haid; C Nemes; M Jagoutz-Herzlinger; S Redtenbacher
Journal:  Br J Surg       Date:  2005-06       Impact factor: 6.939

2.  Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study.

Authors:  Adriana J Maaskant-Braat; Lonneke V van de Poll-Franse; Adri C Voogd; Jan Willem W Coebergh; Rudi M Roumen; M Cathelijne Tutein Nolthenius-Puylaert; Grard A Nieuwenhuijzen
Journal:  Breast Cancer Res Treat       Date:  2010-08-03       Impact factor: 4.872

3.  Factors that determine whether a patient receives completion axillary lymph node dissection after a positive sentinel lymph node biopsy for breast cancer in British Columbia.

Authors:  Nava Aslani; Todd Swanson; Hagen Kennecke; Ryan Woods; Noelle Davis
Journal:  Can J Surg       Date:  2011-08       Impact factor: 2.089

4.  Comparison of two models for predicting non-sentinel lymph node metastases in sentinel lymph node-positive breast cancer patients.

Authors:  Giovanni D'Eredita'; Vito Leopoldo Troilo; Fernando Fischetti; Giuseppe Rubini; Tommaso Berardi
Journal:  Updates Surg       Date:  2011-05-31

Review 5.  Clinical significance and management of sentinel node micrometastasis in invasive breast cancer.

Authors:  Sadaf Jafferbhoy; Billy McWilliams
Journal:  Clin Breast Cancer       Date:  2012-10       Impact factor: 3.225

6.  Assessment of the performance of the Stanford Online Calculator for the prediction of nonsentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients.

Authors:  Jeffrey S Scow; Amy C Degnim; Tanya L Hoskin; Carol Reynolds; Judy C Boughey
Journal:  Cancer       Date:  2009-09-15       Impact factor: 6.860

7.  Sentinel lymph node micrometastasis as a predictor of axillary tumor burden.

Authors:  David J Dabbs; Mark Fung; Douglas Landsittel; Kim McManus; Ronald Johnson
Journal:  Breast J       Date:  2004 Mar-Apr       Impact factor: 2.431

8.  Influence of isolated tumor cells in sentinel nodes on outcome in small, node-negative (pT1N0M0) breast cancer.

Authors:  Marjut H K Leidenius; Jaana H Vironen; Päivi S Heikkilä; Heikki Joensuu
Journal:  Ann Surg Oncol       Date:  2009-10-09       Impact factor: 5.344

9.  Micrometastases or isolated tumor cells and the outcome of breast cancer.

Authors:  Maaike de Boer; Carolien H M van Deurzen; Jos A A M van Dijck; George F Borm; Paul J van Diest; Eddy M M Adang; Johan W R Nortier; Emiel J T Rutgers; Caroline Seynaeve; Marian B E Menke-Pluymers; Peter Bult; Vivianne C G Tjan-Heijnen
Journal:  N Engl J Med       Date:  2009-08-13       Impact factor: 91.245

10.  International multicenter tool to predict the risk of nonsentinel node metastases in breast cancer.

Authors:  Tuomo J Meretoja; Marjut H K Leidenius; Päivi S Heikkilä; Gabor Boross; István Sejben; Peter Regitnig; Gero Luschin-Ebengreuth; Janez Žgajnar; Andraz Perhavec; Barbara Gazic; György Lázár; Tibor Takács; Andras Vörös; Zuhair A Saidan; Rana M Nadeem; Isabella Castellano; Anna Sapino; Simonetta Bianchi; Vania Vezzosi; Emmanuel Barranger; Ruben Lousquy; Riccardo Arisio; Maria Pia Foschini; Shigeru Imoto; Hiroshi Kamma; Tove F Tvedskov; Niels Kroman; Maj-Brit Jensen; Riccardo A Audisio; Gabor Cserni
Journal:  J Natl Cancer Inst       Date:  2012-11-01       Impact factor: 13.506

View more
  4 in total

1.  Gene promoter hypermethylation is found in sentinel lymph nodes of breast cancer patients, in samples identified as positive by one-step nucleic acid amplification of cytokeratin 19 mRNA.

Authors:  E Martín-Sánchez; E Pernaut-Leza; S Mendaza; A Cordoba; F Vicente-Garcia; I Monreal-Santesteban; J Pérez Vizcaino; M J Díaz De Cerio; N Perez-Janices; I Blanco-Luquin; D Escors; A Ulazia-Garmendia; D Guerrero-Setas
Journal:  Virchows Arch       Date:  2016-04-21       Impact factor: 4.064

2.  Predictive Factors for Non-Sentinel Lymph Node Metastasis in the Case of Positive Sentinel Lymph Node Metastasis in Two or Fewer Nodes in Breast Cancer.

Authors:  Chie Toshikawa; Yu Koyama; Masayuki Nagahashi; Kumiko Tatsuda; Kazuki Moro; Junko Tsuchida; Miki Hasegawa; Toshiyuki Niwano; Naoko Manba; Mayuko Ikarashi; Hitoshi Kameyama; Takashi Kobayashi; Shin-Ichi Kosugi; Toshifumi Wakai
Journal:  J Clin Med Res       Date:  2015-06-09

3.  Blood-derived non-extracellular vesicle proteins as potential biomarkers for the diagnosis of early ER+ breast cancer and detection of lymph node involvement.

Authors:  Rod Tucker; Ana Pedro
Journal:  F1000Res       Date:  2018-03-06

4.  Nomogram models for stratified prediction of axillary lymph node metastasis in breast cancer patients (cN0).

Authors:  Xin Gao; Wenpei Luo; Lingyun He; Lu Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-30       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.